Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06503614 · ClinicalTrials.gov registry record · Phase 2
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
A Phase 2 study of Non-muscle Invasive Bladder Cancer and Non-Muscle Invasive Bladder Urothelial Carcinoma, sponsored by John Sfakianos.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT06503614 is a Phase 2 study of Non-muscle Invasive Bladder Cancer and Non-Muscle Invasive Bladder Urothelial Carcinoma that is actively recruiting participants, run by John Sfakianos. The registered enrollment target is 60 participants, below the 231-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06503614, a Phase 2 study of Non-muscle Invasive Bladder Cancer and Non-Muscle Invasive Bladder Urothelial Carcinoma, is actively recruiting participants, sponsored by John Sfakianos.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do not have cancer in situ (CIS) but do have high grade papillary urothelial cancer. Eligible patients will be enrolled to receive up to 13 cycles of monthly combination of monalizumab and durvalumab. Both monalizumab and durvalumab will be administered intravenously (IV) every 28 days.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Monalizumab
Study Locations (3)
Florida
- Moffitt Cancer Center - Tampa
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06503614
The ClinicalTrials.gov registry entry for NCT06503614 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (74% lower). The listed sponsor is John Sfakianos, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT06503614 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT06503614 about?
NCT06503614 is a clinical study titled "A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer". This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do no...
What is the current status of trial NCT06503614?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-02-24. Estimated completion is 2027-12.
What conditions does trial NCT06503614 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma.
What interventions are being tested in trial NCT06503614?
The interventions under investigation include: Durvalumab (DRUG), Monalizumab (DRUG).
Who is sponsoring clinical trial NCT06503614?
This trial is sponsored by John Sfakianos, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06503614 being conducted?
This trial has 3 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
RECRUITING · Phase 2
-
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
COMPLETED · Phase 2
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Non-muscle Invasive Bladder Cancer
All registered trials for this condition
Non-Muscle Invasive Bladder Urothelial Carcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.